SCHEMBL2814716

SCHEMBL2814716

Oc1cccc(-c2cn3c(n2)c(Cl)nc2ccccc23)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 13/20 0.50
ADORA1 P30542 5/20 0.50
LMNA P02545 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CA2 P00918 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
TYMS P04818 1/20 0.42
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
NFKB1 P19838 1/20 0.41
RAB9A P51151 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814103 0.85 ADORA2A (0.67) ADORA2AADORA1LMNAKDM4EALDH1A1
SCHEMBL2817874 0.85 ADORA2A (0.64) ADORA2AADORA1LMNAKDM4EALDH1A1
SCHEMBL2818321 0.81 ADORA2A (0.56) ADORA2AADORA1LMNAKDM4EALDH1A1
SCHEMBL2818069 0.81 ADORA2A (0.71) ADORA2AADORA1LMNAKDM4EALDH1A1
SCHEMBL2817781 0.81 ADORA2A (0.48) ADORA2AADORA1LMNAKDM4EALDH1A1
SCHEMBL2818350 0.79 ADORA2A (0.45) ADORA2AADORA1LMNAKDM4EALDH1A1
SCHEMBL2816969 0.77 ADORA2A (0.46) ADORA2AADORA1LMNAKDM4EALDH1A1
SCHEMBL2816945 0.76 FYN (0.50) ADORA2AADORA1LMNACA2ADORA3
SCHEMBL2816752 0.74 ADORA2A (0.70) ADORA2AADORA1LMNAKDM4EALDH1A1
SCHEMBL2813910 0.74 ADORA2A (0.67) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US claimed
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 EP disclosed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US disclosed
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS IDH3A, NRAS, KRAS ADORA2A 1818/4885ADORA1 1985/4885LMNA 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.